Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

21.90USD
18 Aug 2017
Change (% chg)

$0.10 (+0.46%)
Prev Close
$21.80
Open
$21.65
Day's High
$22.12
Day's Low
$21.40
Volume
421,807
Avg. Vol
809,389
52-wk High
$33.00
52-wk Low
$13.60

ACOR.O

Chart for ACOR.O

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $1,021.65
Shares Outstanding(Mil.): 46.65
Dividend: --
Yield (%): --

Financials

  ACOR.O Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -0.94 -- --
ROI: -3.56 2.83 14.89
ROE: -6.31 5.09 16.13

Pharma industry rallies around Acorda's appeal of patent ruling

Trade groups representing the pharmaceutical and biotech industries on Monday urged a federal appeals court to reverse a ruling that invalidated key patents held by Acorda Therapeutics Inc on its multiple sclerosis drug Ampyra.

Aug 16 2017

Deals of the day-Mergers and acquisitions

Aug 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Aug 07 2017

Acorda Therapeutics investor calls for company to explore sale

A New York-based hedge fund that owns 17 percent of Acorda Therapeutics Inc on Monday called on the U.S. developer of drugs targeting neurological disorders to explore a sale, according to a regulatory filing with the U.S. Securities and Exchange Commission.

Aug 07 2017

UPDATE 1-Acorda Therapeutics investor calls for company to explore sale

Aug 7 A New York-based hedge fund that owns 17 percent of Acorda Therapeutics Inc on Monday called on the U.S. developer of drugs targeting neurological disorders to explore a sale, according to a regulatory filing with the U.S. Securities and Exchange Commission.

Aug 07 2017

BRIEF-‍Scopia Capital Management LP reports 16.5 pct stake in Acorda Therapeutics as of Aug 4 - SEC filing​

* ‍Scopia Capital Management LP reports 16.5 percent stake in Acorda Therapeutics Inc as of August 4 - SEC filing​

Aug 07 2017

Acorda Therapeutics investor calls for company to explore sale

Aug 7 A New York-based hedge fund which owns 17 percent of Acorda Therapeutics Inc called on the U.S. developer of drugs targeting neurological disorders on Monday to explore a sale of the company, according to a regulatory filing with the U.S. Securities and Exchange Commission.

Aug 07 2017

BRIEF-Acorda Therapeutics Q2 non-GAAP earnings per share $0.29

* Acorda provides financial and pipeline update for second quarter 2017

Jul 27 2017

BRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics as of June 27, 2017

* Christopher M. James reports a 5.9 percent passive stake in Acorda Therapeutics Inc as of June 27, 2017- sec filing Source text (http://bit.ly/2tz6Pgg) Further company coverage:

Jul 07 2017

BRIEF-Acorda submits new drug application to U.S. Food And Drug Administration

* Acorda submits new drug application to U.S. Food And Drug Administration for inbrijatm (CVT-301, levodopa inhalation powder)

Jun 29 2017

BRIEF-Acorda Therapeutics, in May 2017, filed planned appeal of decision on 4 invalidated patents with U.S. court of appeals for federal circuit

* Acorda Therapeutics -in May 2017, filed planned appeal of decision on four invalidated patents with united states court of appeals for federal circuit

Jun 09 2017

Earnings vs. Estimates